Mineralys in Radnor Sees Stock Price Explode

Mineralys in Radnor Sees Stock Price Explode After Hypertension Drug Test
The Radnor biopharmaceutical firm Mineralys Therapeutics saw its stock price hit new heights Monday after a positive late-stage clinical trial showed promise
Mineralys Therapeutics prices $175M stock offering
Mineralys Therapeutics (MYLS) priced an underwritten public offering of ~12.96M shares at a public offering price of $13.50 per share. The aggregate gross proceeds are expected to be ~$175M. Underwriters have a 30-day option to purchase up to an additional ~1.
Mineralys Therapeutics' stock price explodes after lorundrostat study results
A Radnor biopharma firm saw its stock price skyrocket after the company posted positive late-stage clinical trial results for its lead new drug candidate.
Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock
BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel and Wells Fargo Securities are acting as joint book-running managers for the offering. LifeSci Capital is acting as lead manager and H.C. Wainwright & Co. is acting as co-manager for the offering.
Mineralys' stock jumps as hypertension drug posts double clinical wins
Mineralys Therapeutics enjoyed a big stock bump after its aldosterone synthase inhibitor chalked up wins in two types of hypertension.
Mineralys Therapeutics Announces Proposed Public Offering of Common Stock
Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone,
Mineralys Therapeutics 12.96M share Secondary priced at $13.50
The deal size was reduced to $175M from $250M and priced below last closing price of $14.30. BofA, Evercore ISI, Goldman Sachs, Stifel and
Mineralys Reports Positive Results for Hypertension Drug Lorundrostat
Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced positive topline results from its pivotal Launch-HTN Phase 3 and Advance-HTN Phase 2 trials evaluating lorundrostat for the treatment of uncontrolled
BioPharma Dive5d
Mineralys shares climb on study data for blood pressure drug
Findings from a pair of studies in tough-to-treat hypertension establish Mineralys’ drug as a “derisked, almost-commercial ...
Mineralys: Prospects Just Got Better With Successful Pivotal Data Readouts
Primary endpoints of both Advance-HTN and Launch-HTN studies, using lorundrostat to treat patients with hypertension were met ...
BioSpace5d
Mineralys’ Hypertension Drug Drops Blood Pressure in Phase II/III, Setting Up Market Clash
Mineralys’ shares got a more than 50% boost Monday morning as new data showed its hypertension drug reduced blood pressure in ...
GlobalData on MSN5d
Mineralys’s stock soars as hypertension pill scores in two pivotal trials
Mineralys Therapeutics’s oral hypertension therapy, lorundrostat, has met the primary endpoint in two pivotal studies, ...
Medscape3d
Positive Topline Results for Lorundrostat in Hypertension
Two pivotal trials of the aldosterone synthase inhibitor have shown positive results for lorundrostat in uncontrolled and ...
Bank of America Securities Sticks to Its Buy Rating for Mineralys Therapeutics, Inc. (MLYS)
In a report released yesterday, Tim Anderson from Bank of America Securities maintained a Buy rating on Mineralys Therapeutics, Inc. (MLYS – ...